Why Did Galera Therapeutics Shares Plunge To All Time Lows Today?

Galera Therapeutics Inc GRTX stock has plunged to all-time since its listing in November 2019 in reaction to disappointing data from the Phase 3 ROMAN trial of avasopasem manganese in severe oral mucositis (SOM) patients with locally advanced head and neck cancer (HNC) undergoing standard-of-care radiotherapy.
The trial did not meet its primary endpoint of reduction in the incidence of SOM. The Company continues to analyze the results.
Key findings:
16% relative reduction in the incidence of SOM in the avasopasem treatment group (54%) vs. placebo group (64%), the primary endpoint.
56% relative reduction in the number of days of SOM in the avasopasem treatment group (8 days) vs. placebo group (18 days).
27% relative reduction in the severity in the avasopasem treatment group (24%) vs. placebo.
Avasopasem was generally well tolerated with similar rates of adverse events in the active and placebo arms.
Oral mucositis is a side effect of radiation therapy characterized by severe pain, inflammation, ulceration, and bleeding of the mouth.
Related: Galera's Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study.
Price Action: GRTX shares dropped 70.7% to $2.17 during the premarket session on the last check Tuesday.